Cardiac dysfunction is often observed in patients with cancer also representing a serious problem limiting chemotherapeutic intervention and even patient survival. In view of the recently established role of the immune system in the control of cancer growth, the present work has been undertaken to investigate the effects of a panel of the most important inflammatory cytokines on the integrity and function of mitochondria, as well as of the cytoskeleton, two key elements in the functioning of cardiomyocytes. Either mitochondria features or actomyosin cytoskeleton organization of in vitro-cultured cardiomyocytes treated with different inflammatory cytokines were analyzed. In addition, to investigate the interplay between tumor growth and cardiac function in an in vivo system, immunocompetent female mice were inoculated with cancer cells and treated with the chemotherapeutic drug doxorubicin at a dosing schedule able to suppress tumor growth without inducing cardiac alterations. Analyses carried out in cardiomyocytes treated with the inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interferon γ (IFN-γ), interleukin 6 (IL-6), IL-8, and IL-1β revealed severe phenotypic changes, for example, of contractile cytoskeletal elements, mitochondrial membrane potential, mitochondrial reactive oxygen species production and mitochondria network organization. Accordingly, in immunocompetent mice, the tumor growth was accompanied by increased levels of the inflammatory cytokines TNF-α, IFN-γ, IL-6, and IL-8, either in serum or in the heart tissue, together with a significant reduction of 
system of cardiomyocytes, due to the systemic inflammation associated with cancer growth, could be responsible for remote cardiac injury and impairment of systolic function observed in vivo.
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| INTRODUCTION
Cancer has to be considered as a complex syndrome that can result in a series of valuable clinical alterations, including cachexia and progressive loss of body weight, often correlated with a poor prognosis. Cancer growth has also been associated with the occurrence of heart disease (Arámbula-Garza et al., 2016; Ishida et al., 2017; Tilemann, Heckmann, Katus, Lehmann, & Müller, 2018) . These alterations have been characterized in detail and have been referred to as "heart cachexia." Among these changes are echocardiographic modifications, a decreased heart size, a loss of the fat surrounding the heart, alterations of cardiomyocytes morphology, and integrity with increased catabolic activity and autophagic triggering. Investigations carried out in human patients with different forms of cancer found an increased incidence of cardiovascular autonomic insufficiency, decreased heart rate variability, an increased resting heart rate, and a decreased resting blood pressure (Guo et al., 2015; Guzzetti, Costantino, Vernocchi, Sada, & Fundarò, 2008; Lainscak, Dagres, Filippatos, Anker, & Kremastinos, 2008; Seviiri et al., 2018) . In addition, it is well-known that several agents capable of at least partially impairing tumor growth also exert a plethora of unwanted effects, including heart failure (HF). The most described chemotherapy agent able to induce cardiopathy is the anthracycline doxorubicin (DOXO), a drug of widespread use in the clinical practice since many years and capable to exert antitumor activity against several different forms of cancers thanks to its DNA intercalating activity.
Importantly, short or long term "toxic effects" either of cancer per se or of anticancer treatment are still a matter of study because the protection towards paraneoplastic toxic syndrome, including cardiac cachexia, or unwanted side effects of anticancer drugs, such as DOXO, are still an objective of anticancer research, that is finalized to lower tumor growth minimizing toxic insults.
In this study we hypothesized that the deterioration of cardiac functions observed in patients with cancer, regardless of chemotherapy, could be due to the alterations induced by inflammatory cytokines associated with tumor growth on cytoskeleton and mitochondrial network of cardiomyocytes.
| MATERIALS AND METHODS

| Cell culture and treatments
Cardiomyoblast H9c2 derived from female rat were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and maintained at 37°C in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA).
H9c2 cells were serum starved and treated with 1 μM retinoic acid (Sigma-Aldrich, Saint Louis, MO) for 48 hr and before and during treatment with 50 ng/ml recombinant rat cytokines tumor necrosis factor α (TNF-α), interferon γ (IFN-γ), interleukin 1β (IL-1β), IL-8, (R&D Systems, Minneapolis, MN) for additional 48 hr.
Low passage-number cell line CT26, isolated for the first time from BALB/c female mice (Corbett, Griswold, Roberts, Peckham, & Schabel, 1975) and obtained from ATCC, was maintained at 37°C, with 5% CO 2 under fully humidified conditions in Roswell Park Memorial Institute-1640 medium (Lonza, Atlanta, GA) supplemented with 10% FBS (EuroClone, Milan, Italy) in the presence of penicillin and streptomycin.
| Animal welfare and ethics statement
Animal studies are performed in compliance with the Animal Research:
Reporting of In Vivo Experiments guidelines (McGrath, Drummond, McLachlan, Kilkenny, & Wainwright, 2010; McGrath & Lilley, 2015) and the European directives (2010/63/EU). Animals were anesthetized with isoflurane before being killed by cervical dislocation. All efforts were made to minimize animal suffering. Mice were housed in groups of three adults per cage and maintained in the standardized conditions in our animal facility at 22 ±2°C room temperature, 40 ± 5% relative humidity and a 12-hr light/dark cycle with dawn/dusk effect, water, and standard pathogen-free chow diet provided ad libitum.
| Mouse experiments
Female BALB/c mice purchased from Charles River (Calco, Italy) were housed in the animal facility at the Istituto Superiore di Sanità (Rome, Italy) and manipulated in accordance with the local Ethical Committee guidelines. 2 × 10 6 CT26 cells were injected subcutaneously (s.c.) to induce a subcutaneous tumor. To suppress tumor growth, mice were treated intravenously (i.v.) with DOXO. To avoid both acute and chronic DOXO-mediated cardiotoxicity (Abdullah et al., 2019) , a fractionated dose of DOXO (10 mg/kg) was administered once a week for 2 weeks and then cardiac function and structure were evaluated 2 weeks after the initiation of treatment. The body weight of the mice was assessed every day after tumor implantation, and the tumor length and width were measured using a digital caliper once the tumor was palpable. For the analysis of the drug effects, tumors were removed to calculate the body weight as the whole body weight minus the tumor weight. Three independent experiments considering six mice in each experimental group were performed.
| RNA preparation and the quantitative realtime polymerase chain reaction
Total RNA was extracted from tumor tissue by using TRIzol (Thermo Fisher Scientific, Waltham, MA) and purified by using RNA purelink mini kit (Invitrogen; Life Technologies, Monza, Italy). The concentration and purity of the RNA solution were determined by using a NanoDrop spectrophotometer (Thermo Fisher Scientific), whereas its overall quality was analyzed using the Agilent 2100 bioanalyser with an RNA LabChip (RNA 6000 Nano kit; Agilent, Santa Clara, CA 
| Echocardiography
Mice were anesthetized with Isoflurane (1.5% in 100% of oxygen) and placed in a supine position on a heated operating table to maintain core body temperature at 37°C. Echocardiography (SONO-LINE G50; Siemens AG, Erlangen, German), was performed as described by Patrizio et al. (2007) . Briefly, the chest was shaved using a chemical hair remover and warmed ultrasound gel was applied to the surface of the thorax to optimize the visibility of the 
| Histological analysis
Hearts were fixed in 10%-buffered formalin (Bio Optica, Milan Italy), embedded in paraffin and cut into 5 μm sections. Histological analysis was performed as described previously (Marano et al., 2004) .
Specifically, LV sections were stained by the Sirius red/picric acid method to determine LV fibrosis by quantitative morphometry (Morphometric; Universal Imaging Corporation, Downingtown, PA).
| Blood for assay of serum
Blood was collected from the retro-orbital venous sinuses of mice before sacrifice. The sample was allowed to clot for 45 min (to facilitate the removal of all the platelets and precipitates) and then centrifuged at 10,000g for 15 min at +4°C. The serum was stored at −80°C before assay. NIH Image 1.62 software. The density of each band in the same gel was analyzed, values were totaled, and then the percent distribution across the gel was detected.
| Total antioxidant capacity
| ATP determination
To quantify ATP in control and treated-H9c2 cells we used a bioluminescence assay (Thermo Fisher Scientific) following the manufacturer's instructions. This ATP determination assay is extremely sensitive and it is based on the luciferase's absolute requirement for ATP in producing light (emission maximum~560 nm at pH 7.8).
| Immunofluorescence
Cells were fixed with 4% paraformaldehyde and then permeabilized by 0.5% (vol/vol) Triton X-100 as reported (Matarrese et al., 2016) . 
| Morphometric analysis
Quantitative evaluations of mitochondrial fragmentation and cell shape alterations were carried out by evaluating at least 50 cells at the same magnification (×1,300). Morphometric analysis was performed by using the ImageJ to measure the average mitochondrial area. To this purpose, red green blue (RGB) images were processed using a customwritten ImageJ macro containing plug-ins that calculate the average area of the mitochondrial particles throughout the cell cytoplasm using the outlines algorithm of the "Analyze Particles" function. The macroassisted algorithm was set to measure all particle sizes larger than the background pixelation, but smaller than the average nuclear size. The average mitochondrial area is expressed as pixel 2 .
2.15 | Flow cytometry
| Mitochondrial membrane potential
The mitochondrial membrane potential of controls and treated H9c2 cardiomiocytes were studied by using 5-5′,6-6′-tetrachloro-1,1′,3, 3′-tetraethyl benzimidazole-carbocyanine iodide probe (JC-1;
Molecular Probes, Eugene, OR), as described (Matarrese et al., 2005) . In line with this method, living cells were stained with 10 μM of JC-1. Tetramethylrhodamine ester 1 μM (TMRM; Molecular Probes) was also used to confirm data obtained by JC-1 (not shown).
| Mitochondrial reactive oxygen species
Cells (5 × 10 4 ) were incubated with 5 μM MitoSOX (red mitochondrial superoxide indicator, Thermo Fisher Scientific) in complete medium, for 30 min at 37°C.
| Fission proteins
Cells were fixed with 4% paraformaldehyde (Carlo Erba, Milano, Italia) and then permeabilized by 0.5% Triton X-100 (Sigma-Aldrich). After Data were analyzed using the Cell Quest Pro software (BD Biosciences).
| Statistical analysis
Results are presented as the mean ± standard deviation (SD). For tests of significance between groups, one-way analysis of variance (ANOVA) was performed. Comparisons between two groups or four groups were performed using the unpaired Student's t test or two-way ANOVA with post hoc tests, respectively (Graphpad software, ver. 5.0). P < 0.05 was considered to indicate a statistically significant difference. All measurements were performed at least in three independent experiments.
3 | RESULTS
| Inflammatory cytokines promote cytoskeleton rearrangement and mitochondrial alterations in cultured cardiomyocytes
In the myocardium, stress-fiber alteration contributes to the development of cardiomyocyte contractile dysfunction and cardiomyopathy (Bravo-Cordero, Magalhaes, Eddy, Hodgson, & Condeelis, 2013) .
On this basis, we tested the effects of the main inflammatory cytokines, IFN-γ, TNF-α, IL-6, IL-8, and IL-1β on cultured H9c2
cardiomyocytes. First, we performed a qualitative analysis of the microfilament system organization, responsible for cell contraction, by fluorescence microscopy after cell staining with TRITC-Phalloidin, which recognizes F-actin, and a specific antibody to myosin. As shown in Figure 1 , 48 hr of treatment with each of these inflammatory cytokines induced a deep alteration either in actin/myosin organization or in cell shape. In particular, cardiomyocytes challenged with the above cytokines lost their bipolar shape along with the compromised orientation of the stress fibers, as also demonstrated by the morphometric analysis (bar graph in Figure 1b ).
| Inflammatory cytokines induce mitochondrial network alterations and upregulation of phospo-DRP1 and hFIS in in vitro-cultured cardiomyocytes
An increasing number of studies place mitochondrial dysfunction as a key event in diseases affecting the heart. In particular, mitochondria form a highly interconnected and dynamic network in cardiomyocytes and provide necessary ATPs for the smooth functioning of the heart (Kuzmicic et al., 2011) . Thus, we investigated the mitochondrial network in H9c2 cardiomyocytes undergoing treatment with IFN-γ, TNF-α, IL-6, IL-1β, and IL-8. We found that although each of these cytokines induced mitochondrial fragmentation (Figure 2a ), normally associated with dysfunctional mitochondria (Disatnik et al., 2013) , as confirmed by the morphometric analysis performed by the ImageJ software to measure average mitochondrial area in cells stained with an anti-TOM20 Ab (Figure 2b ).
In mammals, at least two proteins, the dynamin-related protein 1 (DRP1) and the mitochondrial outer membrane protein hFIS1, 
| colorectal cancer tumor growth induces very early heart dysfunction
Subsequently, we wanted to test our hypothesis in an in vivo model.
To investigate the effects of tumor growth on cardiac function we transplanted sc CT26 colorectal cancer (CRC) cells into female BALB/c mice. In parallel, experiments with DOXO, a well-known potent chemotherapeutic agent (Baxter-Holland & Dass, 2018; Tran, DeGiovanni, Piel, & Rai, 2017) , were also carried out to suppress tumor growth. CT26-bearing mice were subjected to a short treatment with a fractionated dose of DOXO, that is 10 mg/kg given iv once a week for 2 weeks ( Figure S1 ). In untreated animals, tumors grew progressively up to 25 days along with no significant changes in body weight or food intake either during or at the end of the experiment (Figure 5a,c) . Similarly, no signs of cachexia were detected (data not shown). As expected, DOXO was able to inhibit significantly cancer growth (Figure 5a ). In addition, moderate weight loss and slightly increased food intake, indicative of hyperphagia occurrence, were observed in DOXO-treated tumor-bearing mice with respect to the untreated tumor-bearing mice or healthy mice subjected to DOXO treatment (Figure 5b,c) .
To assess the influence of tumor growth and/or DOXO treatment on LV remodeling and function, mice were killed after 25 days tumor cells transplantation and a series of analyses were performed. As shown in Figure 6a , echocardiographic evaluations carried out immediately before the sacrifice of the animals and revealed that CT26-bearing mice had a reduced FS when compared with the healthy control (20.1 ± 2.3% and 34.3 ± 2.1%, respectively). Upon DOXO treatment for 2 weeks, we found that this drug, along with the inhibition of tumor growth, was able to counteract early tumorassociated decrease of FS (28.2 ± 1.1% in DOXO-treated CT26-bearing mice vs. 20.1 ± 2.3% in untreated CT26-bearing mice; Figure 6a ). In contrast, no evidence of cardiac remodeling was found in CT26-bearing mice treated with DOXO. In fact, LV diastolic wall thickness remained unchanged (Figure 6b ) as well as mRNA levels of β-MHC genes (Figure 6c ). By contrast, the levels of natriuretic peptide A (NPPA) mRNA found decreased in untreated CT26-bearing mice versus healthy mice, were restored in CT26-bearing mice undergoing DOXO treatment (Figure 6d ). Importantly, in our experimental conditions, the short-term administration of DOXO in healthy mice caused no cardiac dysfunction, remodeling or fibrosis, due to the myocardial interstitial collagen reorganization, as revealed by echocardiographic, biochemical and histological analyses (Figure   6a ,b; Figure S2 ). Of interest, the transcript analysis of the proinflammatory cytokine TNF-α, which disclosed a clear-cut increased production in ventricles of tumor-bearing mice, also revealed a significant decrease in DOXO-treated CT26-bearing mice (Figure 6e) . Moreover, the levels of IFN-γ and IL-8 remained unchanged whereas the levels of IL-6 and IL-1β increased in tumorbearing animals ( Figure S3 ). As BNP and troponin I are systemic biomarkers for the prediction of cardiac injury, we further evaluated these parameters in plasma. We found the higher levels of BNP in CT26-bearing mice with respect to the healthy counterpart and observed a significant decrease in CT26-bearing mice treated with DOXO ( Figure 6f ). In contrast, the small difference found in plasma level of troponin I among the animal groups was not significant (Figure 6g ). These results highlight the role of tumor development in dictating cardiac damage and the absence of significant adverse cardiac effects of the short-term treatment with DOXO.
| Tumor-induced heart damage correlates with systemic inflammation
Chronic systemic inflammation is proposed as an underlying mechanism for the development of cardiac injury (Bye et al., 2016) .
Thus, in light of the in vitro data, we investigated the expression of the major systemic and tumor-associated inflammatory cytokines, such as TNF-α, IL-1β, IL-6, IL-8, and IFN-γ, reported to be implicated in the development of cardiac dysfunction (Mann, 2002; Zhao et al., 2013 comparison to the healthy counterpart, these animals exhibited a highly significant up-modulation of plasmatic IL-8. Of interest, treatment with DOXO of mice with tumor significantly reduced the plasmatic level of the above cytokines, in particular, IL-8. By contrast, no significant differences in the plasma levels of IL-1β were found among the diverse experimental groups (Figure 7c ). These data suggest, on one hand, the occurrence of systemic inflammation in the presence of tumor and, on the other hand, the capability of DOXO to reduce a systemic production of inflammatory cytokines, specifically IFN-γ in spleen and IL-8 in plasma.
To correlate the increase of systemic proinflammatory cytokines in CT26-bearing mice with the systemic oxidative stress, we further evaluated the TAC, which is indicative of the abundance of antioxidant molecules and enzymes in the blood are able to counteract the effects of ROS/reactive nitrogen species (Du, Anderson, Lortie, Parsons, & Bodnar, 2013) . As shown in Figure 7d , a reduction of TAC was observed in tumor-bearing animals, which was partially counteracted by treatment with DOXO.
| Involvement of autophagy in tumor-induced heart damage
Cardiac homeostasis is also regulated by autophagy. Therefore, we (Figure 8a) . Surprisingly, we also found a significant increase in phospho-ULK1 (p-ULK, Ser 777). Ser 777, a phosphorylation site, is known to be a 5ʹ adenosine monophosphateactivated protein kinase (AMPK) phosphorylation sites in ULK1 (Figure 8a ; Kim, Kundu, Viollet, & Guan, 2011) . In contrast, we did not observe any significant difference of autophagic levels in explanted tumors from untreated or treated tumor-bearing mice (Figure 8b ).
This finding suggests that the autophagy is critical at heart but not at tumor level for DOXO activity. hFIS, Mitofusin 2, and OPA1. As these factors are known as regulators of mitochondrial metabolism, these changes might be directly related to the decreased capacity to oxidize fatty acid substrates often seen in HF (Brown et al., 2017) . The balance between fission and fusion is very important for mitochondrial participation in crucial cellular processes, and disruption of mitochondrial dynamics is emerging as a pathogenetic determinant in prevalent diseases (Dorn, 2015) . However, whether the alterations of mitochondrial fusion and fission processes directly cause LV systolic dysfunction or merely constitute a consequence of this remains to be determined (Ventura-Clapier, Garnier, Veksler, & Joubert, 2011).
| DISCUSSION
Our results provided evidence that tumor growth per se reduces cardiac systolic function, which is apparently associated with the systemic inflammation. Our study includes the analysis of control mice and tumor-bearing mice, both treated or not with a paradigmatic anticancer drug, that is DOXO that has been reported to produce both acute and chronic cardiotoxicity (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004; Octavia et al., 2012) . Strikingly, in our model, the healthy immunocompetent BALB/c mice, administration of DOXO caused no cardiac dysfunction, remodeling or fibrosis, at least in the short term, as revealed by echocardiographic, biochemical, and histological analyses. This discrepancy could be due to: (a) The short-term treatment (once a week for 2 weeks)
carried out in the present study, (b) DOXO could induce cardiac alterations after many years from the end of treatment, as sometimes observed in patients with cancer; and (c) the use of female mice in our study. In fact, some papers recently reported a significant sexual dimorphism in the sensitivity to DOXO toxicity (Hequet et al., 2004; Moulin, Piquereau et al., 2015; Štěrba et al., 2013) . A critical role of mitochondrial dysfunction, altered energy metabolism, together with altered cardiolipin homeostasis, was hypothesized to play a role in the observed sex differences in vivo (Moulin, Solgadi et al., 2015; Mejia, Cole, & Hatch, 2014) . The fact that cancer growth per se was able to interfere with heart activity was also clearly demonstrated by echocardiographic signs of heart function impairment, such as a significant reduction of FS. On this basis, we hypothesized that humoral factors secreted from and/or induced by the tumor could be responsible for promoting LV systolic dysfunction.
Our murine model, characterized by host immunocompetence, allowed us to identify immunological factors, inflammatory responses, and metabolic signals that cannot be investigated in animal models that lack the immunological components, such as nude and severe combined immunodeficient mice. In fact, for preventing rejection of xenografted human cells, immunocompromised mice are usually used. At variance, immune responses and their alterations are nowadays thought to play a key role in tumor development and progression (Budhu, Wolchok, & Merghoub, 2014) so that the immunocompetent tumor-bearing mice have been proposed to represent a suitable model. Accordingly, in our study, host immune response (resulting in an increase of proinflammatory cytokines synthesis at tumor and spleen level) appeared to be observable in tumor-bearing mice. Importantly, this picture of systemic inflammation was tightly correlated to CT26-bearing mice heart dysfunction.
In fact, these animals were characterized by a progressive tumor growth associated to both tissue inflammation (with elevated levels mainly of IL-1β and IFN-γ), and systemic inflammation (with increased inflammatory cytokines such as IL-8, IFN-γ, TNF-α, and IL-6 at the plasma level), and by cardiac systolic dysfunction with a local increase of TNF-α levels.
Cardiac homeostasis is also regulated by autophagy and cardiacspecific reduction of autophagy could result in contractile dysfunction, increased levels of polyubiquitinated proteins and increased apoptosis (Nakai et al., 2007) . Moreover, it is possible that autophagy, to prevent protein aggregation, could degrade myofibrillar proteins cleaved from the sarcomere during cardiac atrophy thus preserving cardiac function. Accordingly, deregulated autophagic processes have been associated with heart dysfunctions, including cardiomyopathies, cardiac hypertrophy, ischemic heart disease, HF, and ischemia-reperfusion injury (Choi, Ryter, & Levine, 2013; Kirshenbaum, 2012) . Indeed, in the heart, autophagy activation can be beneficial or detrimental depending on the physiopathological context (Lavandero et al., 2013; Sciarretta, Maejima, Zablocki, & Sadoshima, 2018) . Hence, more in general, a differential role for autophagy in acute versus chronic heart disease has been suggested:
Short-term activation of autophagy may confer cardiac benefits, whereas sustained autophagy could have detrimental effects (Delbridge, Mellor, Taylor, & Gottlieb, 2017) . In our study, ventricle tissues from tumor-bearing mice were found to exhibit a significant decrease of autophagy that was prevented by short-term treatment with DOXO. In this regard, many studies showed that DOXO can upregulate cardiac autophagy contributing to DOXO-dependent cardiotoxicity Kobayashi, Xu, Chen, & Liang, 2012 ; D. L. Li et al., 2016) . By contrast, other studies reported that autophagy activation could protect from DOXO-induced cardiotoxicity (Bartlett, Trivedi, & Pulinilkunnil, 2017; S. Li et al., 2014; Pizarro et al., 2016) . Anyway, the role of autophagy in DOXO cardiotoxicity is still a matter of debate as it is unclear whether DOXO induces or disrupts the cardiac autophagic activity and if cardiomyocyte autophagy modulation could be beneficial or detrimental. To complicate this scenario, it has also been hypothesized that an increased AMP/ATP ratio could activate AMPK, a sensor a cell energy levels, by phosphorylation at Thr172 (Kim, Kundu, Viollet, & Guan, 2011) and that the active AMPK can stimulate the autophagy activating kinase ULK1 by its direct phosphorylation. This could suggest that, in response to cardiac damage observed in tumorbearing mice, possibly induced by an inflammatory condition due to the tumor growth, AMPK may enhance autophagy through the direct activation of ULK1 by phosphorylating Ser 777 via a mammalian target of rapamycin independent pathway (Koleini & Kardami, 2017) .
All in all, the present study seems to suggest that cancer growth could exert per se, independently from chemotherapy effects, cardiotoxicity at least partially due to a tumor-dependent systemic inflammation that, although could be beneficial for tumor growth control, can also be detrimental for heart integrity and function.
Even if strong evidence suggests that cytokines and other inflammatory molecules, as well as a deregulation of the autophagic BUONCERVELLO ET AL.
